MedAssets PT Raised to $27.00 (MDAS)
Equities researchers at Oppenheimer hoisted their price objective on shares of MedAssets (NASDAQ:MDAS) from $26.00 to $27.00 in a research report issued on Thursday, Stock Ratings Network.com reports. The firm currently has an “outperform” rating on the stock. Oppenheimer’s price objective points to a potential upside of 17.24% from the stock’s previous close.
MedAssets (NASDAQ:MDAS) traded down 11.66% on Thursday, hitting $23.029. The stock had a trading volume of 2,916,745 shares. MedAssets has a 52-week low of $15.40 and a 52-week high of $24.52. The stock has a 50-day moving average of $25.13 and a 200-day moving average of $21.09. The company has a market cap of $1.409 billion and a price-to-earnings ratio of 389.10.
MedAssets (NASDAQ:MDAS) last announced its earnings results on Wednesday, October 30th. The company reported $0.31 earnings per share for the quarter, beating the analysts’ consensus estimate of $0.30 by $0.01. The company had revenue of $166.40 million for the quarter, compared to the consensus estimate of $166.78 million. During the same quarter last year, the company posted $0.32 earnings per share. MedAssets’s revenue was up 1.8% compared to the same quarter last year. On average, analysts predict that MedAssets will post $1.32 earnings per share for the current fiscal year.
In other MedAssets news, CAO Lance M. Culbreth unloaded 2,000 shares of the company’s stock in a transaction dated Tuesday, October 22nd. The shares were sold at an average price of $26.45, for a total value of $52,900.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.
A number of other analysts have also recently weighed in on MDAS. Analysts at Jefferies Group raised their price target on shares of MedAssets from $25.00 to $30.00 in a research note to investors on Thursday. They now have a “buy” rating on the stock. Separately, analysts at FBR & Co. initiated coverage on shares of MedAssets in a research note to investors on Thursday. They set a “market perform” rating on the stock. Finally, analysts at FBR Capital Markets initiated coverage on shares of MedAssets in a research note to investors on Thursday. They set a “market perform” rating and a $24.00 price target on the stock. Eight analysts have rated the stock with a hold rating, three have issued a buy rating and one has given a strong buy rating to the company. MedAssets currently has a consensus rating of “Hold” and a consensus price target of $26.98.
MedAssets, Inc (NASDAQ:MDAS) provides technology-enabled products and services.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.